Could a rheumatoid arthritis drug protect High-Risk kidneys?
NCT ID NCT05237388
First seen May 08, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tested whether baricitinib, a drug used for arthritis, can safely lower protein in the urine of African American adults with APOL1 gene-related chronic kidney disease. Eight participants took the drug to see if it reduced kidney damage. The goal was to manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Research at Pickett Road
Durham, North Carolina, 27705, United States
Conditions
Explore the condition pages connected to this study.